Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Crucell Terug naar discussie overzicht

Draadje vogelgriep - Deel 2

318 Posts
Pagina: «« 1 ... 11 12 13 14 15 16 »» | Laatste | Omlaag ↓
  1. flosz 13 maart 2009 20:52
    Haha, mooi Jay!
    *************

    Is van even geleden...maar toch.

    Wayne Pisano - Flu Vaccines
    Published on Dec 17, 2008 in Technology

    Dr. Moira Gunn speaks with Wayne Pisano, the CEO of the world's largest flu vaccine producer Sanofi Pasteur, and asks him whether Americans receive the same vaccination as Europeans do, and how you can prepare for a global flu epidemic

    odeo.com/episodes/23771390-Wayne-Pisa...

    Pandemic ready in 3 years….één minuut later in 3 to 4 years (vanaf ong. 06.30U.)

    Wayne Pisano van:
    Je komt zeker over mijn vriend Ronald Brus praten”, lachte Wayne Pisano, de hoogste baas bij de vaccinactiviteiten van het Franse concern, na afloop van de bijeenkomst. Pisano ziet trouwens wel overlap in de vaccins die Crucell en Sanofi maken, „maar dat is bij veel van onze concurrenten het geval”.
    Desgevraagd gaf de bestuurder gisteren schoorvoetend aan dat hij bij een overname van het Leidse bedrijf geen mededingingsproblemen zou verwachten. „Er zijn niet veel beschikbare vaccinmakers en wij werken weliswaar al samen met Crucell, maar dat geldt voor meerdere grote medicijnenfabrikanten. Er zijn dus meer potentiële gegadigden voor dat bedrijf. Dat zeggen analisten tenminste.” www.farmaactueel.nl/index.php?id=8353
  2. [verwijderd] 14 maart 2009 10:35
    Wellicht al gepost, misschien ook niet, ik kon het nog niet vinden.

    Sanofi blueprints big vaccine plant for Mexico
    March 11, 2009 — 3:19pm ET | By John Carroll
    RELATED STORIES
    Sanofi-Aventis CEO Chris Viehbacher journeyed to Mexico to announce a new $126 million facility to produce seasonal influenza vaccine-with a built-in option to switch to pandemic vaccines--for the Latin American market. The president of Mexico, Felipe Claderon, joined French President Nicolas Sarkozy for the announcement.
    "This investment illustrates Sanofi-Aventis' local approach to global health," said Viehbacher. "This facility will benefit public health in Mexico and the Latin American region, in the context of influenza pandemic preparedness."
    Once complete, Sanofi will work with Birmex--Laboratorio de Biológicos y Reactivos de México--on the manufacturing and distribution of vaccines. To be completed in four years, the plant will have the capacity to produce up to 25 million doses of new flu vaccine each year. And it will be built so that it can switch to manufacturing a pandemic vaccine in the event of an outbreak.

    www.fiercevaccines.com/story/sanofi-b...

    de vraag: perc.6 inside??
  3. aossa 14 maart 2009 12:51
    quote:

    soldaat schreef:

    de vraag: perc.6 inside??
    Volgens mij weer een 'hybride plant'

    "... facility to produce seasonal influenza vaccine-with a built-in option to switch to pandemic vaccines--for the Latin American market"
  4. [verwijderd] 14 maart 2009 13:23
    quote:

    aossa schreef:

    [quote=soldaat]de vraag: perc.6 inside??[/quote]
    Volgens mij weer een 'hybride plant'

    "... facility to produce seasonal influenza vaccine-with a built-in option to switch to pandemic vaccines--for the Latin American market"
    Waarbij hybride slaat op seasonal/pandemic; en nog niet eens per.c op eieren/cellen.
  5. aossa 14 maart 2009 14:33
    quote:

    maxen schreef:

    [quote=aossa]
    [quote=soldaat]de vraag: perc.6 inside??[/quote]
    Volgens mij weer een 'hybride plant'

    "... facility to produce seasonal influenza vaccine-with a built-in option to switch to pandemic vaccines--for the Latin American market"
    [/quote]

    Waarbij hybride slaat op seasonal/pandemic; en nog niet eens per.c op eieren/cellen.
    Misschien wordt de bulk, in geval van pandemie, aangeleverd uit Lyon of Swiftwater!

    Ik denk ik het niet, omdat in geval van pandemie er zowiezo gebrek zal zijn aan snel ontwikkeld bulk vaccine. Ook omwille van mogelijke calamiteiten lijkt me een geografische spreiding van de installaties een voordeel.

    Wat imo duidelijk is dat Sanofi-Aventis voor 2 productiemethoden te vangen is en dat ze in hun nieuwe fabrieken daarmee rekening houden. Pas na 2010 zal het duidelijk worden of het PER.C6 dan wel eieren wordt.
  6. [verwijderd] 19 maart 2009 22:12
    Reuters

    19.03.2009 18:38

    UPDATE 1-Sanofi pandemic flu vaccine rebuffed by EU agency

    LONDON, March 19 (Reuters) - An experimental pandemic flu vaccine from Sanofi-Aventis (News/Aktienkurs) has been rejected by European regulators because of worries about its effectiveness.

    The European Medicines Agency said on Thursday its experts were concerned over the ability of Sanofi's H5N1 shot Emerflu to trigger the production of enough antibodies against the flu virus.

    Emerflu was expected to be used in adults to protect against pandemic flu, which many experts fear could be triggered by mutations in the H5N1 strain of virus now circulating in birds. It was only intended for use once a pandemic had been declared.

    www.finanznachrichten.de/nachrichten-...

    Meer details hier:

    www.medadnews.com/News/Index.cfm?arti...
  7. [verwijderd] 19 maart 2009 23:58
    quote:

    dedokter schreef:

    Een egte doe-het-zelvert ken niet zonder Crucell
    Tsja.......... vind jij , vind ik en heel veel anderen , maar Freek-Willem heeft dat nog niet voldoende kunnen communiceren.
  8. flosz 26 maart 2009 09:15
    EMERFLU®, pandemic influenza vaccine
    for humans, approved in Australia

    Lyon, France – March 26, 2009 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group
    (EURONEXT: SAN and NYSE: SNY), announced today that its pandemic influenza vaccine for
    human use Emerflu®*, has been granted marketing authorization from the Australian Therapeutic
    Goods Administration (TGA). Emerflu® vaccine is now approved for the prevention of pandemic
    influenza in Australia upon official declaration of a pandemic. Emerflu® vaccine is intended to be
    manufactured and distributed with the identified pandemic strain and used in Australia in accordance
    with official Australian government guidance.
    The Australian approval of Emerflu® vaccine granted today follows the positive recommendation by
    the Australian Drug Evaluation Committee (ADEC) on February 13 2009, based on a review of
    results from clinical trials, which began in late 2004 on H5N1 alum-adjuvanted** inactivated influenza
    vaccine candidates. These trials evaluated the safety and ability of Emerflu® vaccine to elicit a
    protective immune response to the H5N1 strains currently identified by global health authorities and
    experts as a potential source for the next pandemic.
    “The Australian TGA’s recommendation of Emerflu® vaccine marks a new milestone in pandemic
    preparedness,” said Wayne Pisano, President and CEO of sanofi pasteur. According to the World
    Health Organization (WHO), influenza vaccines are considered to be the most important and
    potentially effective intervention for mitigating the effects of an influenza pandemic1. The optimal
    choice of strain and formulation for an effective vaccine will be possible when the pandemic influenza
    strain has emerged1,2. “As the world’s leading influenza vaccine manufacturer, sanofi pasteur aims at
    contributing to the efforts of WHO, Australia and other countries around the world to safeguard
    human health in the event of an influenza pandemic,” added Pisano.
    Sanofi pasteur is actively involved in pandemic preparedness and has invested in a major expansion
    of its influenza vaccine production capacity in the U.S., France, China and Mexico. Sanofi Pasteur is
    also committed to continuing its robust research and development program by exploring strategies for
    protecting more people. This includes the evaluation of new vaccine formulations to generate immune
    responses against other strains of the H5N1 virus as well as the use of adjuvants or
    immunostimulators*** to increase the response to the vaccine.
    en.sanofi-aventis.com/binaries/2009-0...
  9. [verwijderd] 28 maart 2009 08:45
    Indonesie gaat zelf een humaan H5N1 vaccin ontwikkelen en produceren, ik denk met MDCK-cellen . Trials over ca een half jaar is de planning.

    Samenwerking tussen Airlangga Universiteit in Surabaya en Kobe Universiteit Japan.

    -------------------------------------

    Stukje uit artikel over onlangs geopend Level-3 lab in Surabaya. Google vertaald (pakt niet alle woorden mee).

    Friday, 20 March 2009

    "The target we still created the seeds for the bird flu and then mass produced," Nidom said.

    Nidom said, make a bird flu vaccine seed actually easy. Live virus will be inactivated to be used as a vaccine seed.

    The process also does not take long. Nidom to predicts, in 2-3 months of research, seeds to have the vaccine can be created.

    In the next 6-8 months, the vaccine can enter clinical trial, namely mengujikan potency vaccine in humans.

    www.surabayapost.co.id/?mnu=berita&ac...

    Dr Nidom, 1 van DE H5N1 specialisten in Indonesia, werkte mee aan dit onderzoek over de toepassing van MDCK op "H5N1 - seeds":

    jvi.asm.org/cgi/content/abstract/JVI....

    De researchers hebben een eigen blog, met recent nieuws uit Indonesia over H5N1 gevallen(in het Engels).

    birdflucorner.wordpress.com/

  10. [verwijderd] 15 april 2009 14:29
    Een eventuele concurrent voor de anti-lichamen van Crucell:

    April 15, 2009

    Compound may fight bird flu?

    HONG KONG - SCIENTISTS in Hong Kong and the United States have identified a synthetic compound which appears to be able to stop the replication of influenza viruses, including the H5N1 bird flu virus.

    The search for such new 'inhibitors' has grown more urgent in recent years as drugs, like oseltamivir, have become largely ineffective against certain flu strains, like the H1N1 seasonal flu virus. Experts now question how well and how long the drug would stand up against the H5N1, should it unleash a pandemic.

    Researchers in Hong Kong and the Unites States screened some 230,000 compounds that were catalogued with the US National Cancer Institute, and found 20 that could potentially restrict the proliferation of the H5N1.

    The experts told a news conference on Wednesday one of the compounds, compound 1 or NSC89853, showed promise.

    'We have found a compound that is different from oseltamivir but which acts in the same way,' said Leo Poon, a microbiologist at the University of Hong Kong.

    'An analogy would be like we have a door with a keyhole, but the hole has changed, and the key, in this case oseltamivir, can't lock the door anymore,' he told the news conference. 'But we have discovered another keyhole and another key which can lock the door.'

    Their finding was published in the latest issue of the Journal of Medicinal Chemistry.

    In their experiment, the researchers infected separate batches of cultured human cells with seasonal flu virus and H5N1 and found that compound 1 prevented the replication of both types of viruses effectively.

    'Given the problems with drug resistance, this compound can be used to develop a new drug,' said Allan Lau, professor of paediatrics and adolescent medicine at the University of Hong Kong. But he cautioned it would take as much as eight years for such a drug to be available on the market.

    Many advanced countries stock up on oseltamivir and zanamivir, two varieties of the same class of drugs that stops the H5N1 virus from multiplying. But the US Centers for Disease Control and Prevention said in March that 98 per cent of all flu samples from the H1N1 strain were resistant to oseltamivir, which is manufactured by Roche AG and marketed under the brand Tamiflu. -- REUTERS

    www.straitstimes.com/Breaking%2BNews/...

  11. flosz 15 april 2009 16:08
    quote:

    Gert50 schreef:

    'We have found a compound that is different from oseltamivir but which acts in the same way,' said Leo Poon, a microbiologist at the University of Hong Kong.
    Leo Lit Man POON

    Mark Throsby1¤a, Edward van den Brink1¤b, Mandy Jongeneelen1, Leo L. M. Poon2, Philippe Alard3, Lisette Cornelissen4, Arjen Bakker1¤c, Freek Cox1¤a, Els van Deventer1, Yi Guan2, Jindrich Cinatl5, Jan ter Meulen1¤d, Ignace Lasters3, Rita Carsetti6, Malik Peiris2, John de Kruif1¤a, Jaap Goudsmit1*
    1 Crucell Holland BV, Leiden, The Netherlands, 2 Department of Microbiology, The University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region, People's Republic of China, 3 Algonomics NV, Gent-Zwijnaarde, Belgium, 4 Central Veterinary Institute, Wageningen University, Lelystad, The Netherlands, 5 Institute for Medical Virology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany, 6 Laboratory of Cell Biology, Bambino Gesu Children's Research Hospital, Rome, Italy
    Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells.
    www.plosone.org/article/info:doi%2F10...

    ter Meulen J.; van den Brink E.N.; Poon L.L.; Marissen W.E.; Leung C.S.; Cox F.; Cheung C.Y.; Bakker A.Q.; Bogaards J.A.; van Deventer E.; Preiser W.; Doerr H.W.; Chow VT, de Kruif J, Peiris JS, Goudsmit J., van den Brink EN, ter Meulen J, Cox F, Jongeneelen MA, Thijsse A, Throsby M, Marissen WE, Rood PM, Bakker AB, Gelderblom HR, Martina BE, Osterhaus AD, Preiser W, Doerr HW, de Kruif J, Goudsmit J. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants. PLoS Med. 2006. 3(7):e237
    www.plosmedicine.org/article/info:doi...

    www.sars-dtv.nl/final/Final%20Report.pdf
  12. [verwijderd] 16 april 2009 17:23
    Commentaar van een professional over het bovenstaande bericht:

    The news of a new antiviral comes at a Press Conference. That could either mean a blockbuster breakthrough or an unwarranted device to get attention for some otherwise decent but not blockbuster science.

    Unfortunately, the news that "Experts Identify Compound That May Fight Bird Flu" is of the second type:

    .............

    Why there was a Press Conference for this paper is beyond me.

    Blog met onderbouwde uitleg te lezen hier:

    scienceblogs.com/effectmeasure/2009/0...
  13. [verwijderd] 17 april 2009 09:26
    quote:

    Gert50 schreef:

    Een eventuele concurrent voor de anti-lichamen van Crucell:

    April 15, 2009

    Compound may fight bird flu?

    HONG KONG - SCIENTISTS in Hong Kong and the United States have identified a synthetic compound which appears to be able to stop the replication of influenza viruses, including the H5N1 bird flu virus.

    The search for such new 'inhibitors' has grown more urgent in recent years as drugs, like oseltamivir, have become largely ineffective against certain flu strains, like the H1N1 seasonal flu virus. Experts now question how well and how long the drug would stand up against the H5N1, should it unleash a pandemic.

    Researchers in Hong Kong and the Unites States screened some 230,000 compounds that were catalogued with the US National Cancer Institute, and found 20 that could potentially restrict the proliferation of the H5N1.

    The experts told a news conference on Wednesday one of the compounds, compound 1 or NSC89853, showed promise.

    'We have found a compound that is different from oseltamivir but which acts in the same way,' said Leo Poon, a microbiologist at the University of Hong Kong.

    'An analogy would be like we have a door with a keyhole, but the hole has changed, and the key, in this case oseltamivir, can't lock the door anymore,' he told the news conference. 'But we have discovered another keyhole and another key which can lock the door.'

    Their finding was published in the latest issue of the Journal of Medicinal Chemistry.

    In their experiment, the researchers infected separate batches of cultured human cells with seasonal flu virus and H5N1 and found that compound 1 prevented the replication of both types of viruses effectively.

    'Given the problems with drug resistance, this compound can be used to develop a new drug,' said Allan Lau, professor of paediatrics and adolescent medicine at the University of Hong Kong. But he cautioned it would take as much as eight years for such a drug to be available on the market.

    Many advanced countries stock up on oseltamivir and zanamivir, two varieties of the same class of drugs that stops the H5N1 virus from multiplying. But the US Centers for Disease Control and Prevention said in March that 98 per cent of all flu samples from the H1N1 strain were resistant to oseltamivir, which is manufactured by Roche AG and marketed under the brand Tamiflu. -- REUTERS

    www.straitstimes.com/Breaking%2BNews/...

    concurrent? kijk maar eens wie deze vondsten heeft vastgelegd dmv octrooien...er zijn er meerdere die het wiel hebben uitgevonden, maar voor vercommercialiseren heb je denk ik toch echt octrooien nodig.
  14. [verwijderd] 17 april 2009 15:44
    Even een poging tot opheldering:

    deze week was er breed in de wereldpers een verhaal over een "compound" die goed zou werken als virusremmer o.a. voor H5N1.

    Deze stof heet: NSC89853, ofwel :

    4-(4-((3-(2-amino-4-hydroxy-6-methyl-5-pyrimidinyl)propyl)amino)phenyl)-1-chloro-3-buten-2-one.

    pubs.acs.org/doi/abs/10.1021/jm800455g

    Ik ben geen expert, maar NSC89853 lijkt me geen anti-lichaam?

    Vervolgens worden er in een science blog vraagtekens gezet bij de ophef over NSC89853 : geen bijzondere vondst,het duurt minimaal 8 jaar voordat het eventueel op de markt kan komen. Als het tenminste zover komt.

    Flosz vindt op haar geheel eigen wijze dat een zelfde persoon - meneer Poon - is betrokken bij het onderzoek naar antilichamen van Crucell en het onderzoek naar NSC89853 .

    Door de ophef leek het aanvankelijk wat te zijn, maar dat valt reuze mee, of tegen zo je wilt.

    Dus als in de toekomst weer sprake is van "NSC89853" dat weten we er al wat van.

    Octrooien? Lijkt me niet van toepassing, gaat over heel verschillende dingen.

    Concurrent? mmm ..
  15. [verwijderd] 18 april 2009 11:09
    17.04.2009
    NEWS/RESEARCH
    Clinical trial of an avian influenza vaccine
    The Influenza Centre at the Gade Institute, University of Bergen, has, in cooperation with European researchers, developed a new vaccine against the bird flu. This vaccine will now be tested at the Haukeland University Hospital.

    By Kristian Jensen
    Since 2003, 417 people, mainly in South East Asia, have been infected with the bird flu, H5N1. 257 of these died. Should the virus mutate, and become more transmissible between people, a so-called pandemic (a worldwide outbreak affecting a large number of people) might occur. The virus could, in such an event, spread quickly all over the world and cause an unusual amount of serious illness and high mortality. Recent pandemics include the 1918 Spanish Flu, the 1957 Asian flu, and the 1968 Hong Kong Flu. All of these pandemics have their origin in bird flu strains. Many experts and health agencies are currently concerned that the H5N1-virus which has arisen in recent years may evolve into such a pandemic virus.

    This study aims to test a novel vaccine previously not tested on humans. Bird flu vaccines tested in human clinical trials to date have been well tolerated by humans. The study is financed by the EU-project PANFLUVAC, Helse Vest and the University of Bergen, and is approved by SLV and REK. Collaborative partners from several European nations (Great Britain, Italy, Switzerland, Germany, The Netherlands, Norway) are involved in the project, and the vaccine is produced by the vaccine producer Crucell Berna Biotech Ltd under contract from the EU PANFLUVAC project.

    The Influenza Centre aims to recruit 60 healthy individuals aged 19-50 in order to study the immune response elicited by this bird flu vaccine, as well as register any side effects. The vaccine will be tested in three different degrees of strength together with a new strength enhancer (adjuvant) and as vaccine without strength enhancer. It is expected that the participants in this clinical trial will be better protected than those who are not administered such a test vaccine. The study will yield important information for development and efficacy of a new bird flu vaccine, as well as provide information as to how long the vaccine confers protection. This information will be very valuable in the event of a new pandemic.

    www.uib.no/gades/en/nyheter/2009/04/c...
  16. flosz 18 april 2009 17:13
    The Third International Conference on:
    INFLUENZA VACCINES FOR THE WORLD - IVW 2009
    will be taking place at the Palais de Festival, Cannes, South of France on 27-30 April 2009.
    www.panfluvac.org/news/assets/IVW_09.pdf

    Influenza epidemics remain a burden to both human health and national economies, as witnessed by the recent advance of pathogenic avian H5N1 influenza virus. While the numbers of human deaths in Europe have remained relatively low, the presence of such cases in Turkey demonstrates the danger posed by this virus. Now that H5N1 virus has been detected in wild birds in Europe, the PANFLUVAC consortium is committed to creating an efficacious vaccine against this virus, to provide strong protection in a pandemic situation.

    The overall aim of PANFLUVAC is to construct vaccine delivery systems for intranasal and parenteral vaccines. New H5N1 vaccines are based on a current subunit vaccine construction – for immediate evaluation – as well as well-established virosome technology for future development within the project. Pre-clinical evaluation will also permit comparison of the new intranasal vaccines with whole virus vaccine. The vaccine potency will be enhanced by novel adjuvants – ISCOM, glycolipids and lipopeptide adjuvants biosafe for humans - known to promote the dendritic cell activity critical for efficient induction of immune defences. This approach offers both antigen sparing potential and immunopotentiation characteristics. biosafe for humans. With the ISCOM having been employed with experimental influenza vaccines, this will allow the new H5N1 vaccines to be fast-tracked in their development. Accordingly, PANFLUVAC will generate its first H5N1 vaccine for intranasal evaluation within the first 18 months of the project.
    The PANFLUVAC project is also designed to facilitate rapid modification of the vaccine in the face of virus drift. Within the preclinical evaluation, the new vaccines will be tested for the degree of heterotypic cross protection they offer. PANFLUVAC offers a generic vaccine development system to provide safe and efficacious vaccines against influenza, fitting with the “Community Influenza Pandemic Preparedness and Response Planning".

    Partner 1
    Institute of Virology and Immunoprophylaxis (IVI) FDEA/FVO: Federal Veterinary Office of the Federal Department of Economic Affairs, Institute of Virology and Immunoprophylaxis is a Biosafety Level 4 facility with BSL2 and BSL3 laboratories and BSL3+ animal accommodation. The Research Department provides expertise on immunological correlates, particularly to in vitro alternatives to animal experimentation. Therein, the Immunology Group has an established reputation in dendritic cell (DC) biology, modulation of DC responses following interaction with vaccines, and targeting vaccines to DC. The Virology Group has an established reputation in viral RNA biology, providing experience on RNA vaccines and signal transduction pathways in innate responses to virus infection.
    Partner 2
    Crucell is an established influenza vaccine manufacturer and is known for the development of novel vaccine technology. Crucell will provide influenza vaccine and adjuvant expertise by the GMP manufacturing of vaccine formulations for preclinical and clinical testing.
    Partner 3
    National Institute for Biological Standards and Control, (NIBSC) will provide expertise in recombinant virus generation, reagent preparation, in vivo immunological studies and serological analyses. Drs Wood and Robertson are internationally renowned experts in these areas.
    Partner 4
    Retroscreen Virology Ltd is Europe's leading contract Virology research company. The work we conduct is dedicated to creating the next generation of Antivirals and Vaccines in the field of biomedical research. Our research includes both Pre-Clinical and Clinical projects.
    Partner 5
    University of Bergen, The Influenza Centre, The Gade Institute, has its expertise from many facets of the influenza field, in later years especially from studies of the kinetics and quality of the B- and T-cell response, herein memory and mucosal elements, following influenza vaccination. The Centre has many years experience in designing and executing pre-clinical and clinical trials of influenza vaccines.
    Partner 6
    Health Protection Agency, Respiratory & Neurological Virus Laboratory, Respiratory Unit HPA is an independent body that protects the health and well-being of the population. The Agency plays a critical role in protecting people from infectious diseases and in preventing harm when hazards involving chemicals, poisons or radiation occur.
    Partner 7
    Istituto Superiore di Sanità (ISS), Department of Infectious, Immune-mediated and Parasitic Diseases. The National Influenza Centre (NIC) will provide expertise on preclinical and clinical evaluation of serological responses to pandemic influenza vaccines. The group has long-lasting experience in serosurveys aimed at detecting antibodies to human as well as avian influenza strains in human sera using both conventional and recently developed methods.
    Partner 8
    Helmholtz, Zentrum für infektionsforschung studies and investigates pathogens which are medically relevant or can be used as models for researching infection mechanisms.
    Partner 9
    SCIPROM Scientific Project Management is a Swiss company that supports researchers in European and National projects, networks and research consortia. SCIPROM helps with or takes over project construction, submission, negotiation, execution and management.

    www.panfluvac.org/members/members.html

  17. flosz 18 april 2009 17:57
    Osterhaus: 'Onnodige bureaucratie rondom dierproeven'
    Er moet een einde komen aan de bureaucratie rondom dierproeven. De bekende viroloog Ab Osterhaus is het zat. Hij krijgt voor proeven op mensen al na twee maanden toestemming, maar een aanvraag om een dierproef uit te voeren wordt soms pas na zes maanden goedgekeurd. Gevolg is dat steeds meer dierproeven verhuizen naar het buitenland, waar de dieren veel slechter af zijn.
    player.omroep.nl/?aflID=9244973&start...

    Expert Review of Vaccines
    April 2009, Vol. 8, No. 4, Pages 401-423 , DOI 10.1586/erv.09.15
    (doi:10.1586/erv.09.15)

    Current status and progress of prepandemic and pandemic influenza vaccine development
    Isabel Leroux-Roels and Geert Leroux-Roels†
    H5N1 viruses are widely considered to be a probable cause of the next influenza pandemic. Influenza vaccines are considered to form the main prophylactic measure against pandemic influenza. The world’s population is expected to have no pre-existing immunity against the pandemic virus strain and will need two vaccine doses to acquire protective immunity. A pandemic outbreak will spread much faster than it will take for pandemic vaccines to be produced and distributed. Therefore, increasing efforts are being made to develop prepandemic vaccines that can induce broad cross-protective responses and that can be administered as soon as a pandemic is declared or even before, in order to successfully prime the immune system and allow for a rapid and protective antibody response with one dose of the pandemic vaccine. Several vaccine manufacturers have developed candidate pandemic and prepandemic vaccines, predominantly based on reverse-genetics reference strains and have improved the immunogenicity by formulating these vaccines with different adjuvants. Clinical studies with inactivated split-virion or whole-virion vaccines based on H5N1 indicate that two immunizations appear necessary to elicit the level of immunity required to meet licensure criteria. A detailed overview is given of the most successful candidate vaccines developed by seven vaccine manufacturers.
    www.expert-reviews.com/doi/abs/10.158...

    Moving influenza vaccines forward
    Suryaprakash Sambhara and Iain Stephenson†
    …………..
    A further milestone is the licensure in 2007 by European regulators of the first seasonal influenza vaccine produced in a mammalian cell line (Madin–Canin–Darby–Kidney) rather than in eggs. Owing to the large number of embryonated eggs required for virus growth, seasonal vaccine production is a carefully planned process. Cell culture systems increase manufacturing consistency, reduce contamination risks and improve flexibility, particularly if vaccine production is required at short notice to meet unexpected demand. Other mammalian cell lines being used for influenza vaccine production include Vero and PerC-6 cells.
    www.expert-reviews.com/doi/full/10.15...

    Influenza and vaccine development: a continued battle
    Karl G Nicholson
    ……………
    The dependence on eggs to grow influenza virus poses manufacturing problems that occasionally result in delays in distribution and potential shortages of vaccine. Moreover, in the event of a pandemic, the necessary number of high-quality fertile hens’ eggs, and the capacity of manufacturers to process them, is unlikely to match global needs. These are just some limitations of the most widely used influenza vaccines. Importantly, they are well recognized and are being addressed.
    Some significant developments have already occurred – notably the development of oil-in-water adjuvants and the development of cell-culture vaccines.
    www.expert-reviews.com/doi/full/10.15...
  18. [verwijderd] 24 april 2009 19:33
    Werk aan de winkel voor Crucell!

    24 April 2009
    WHO bezorgd over griep in N-Amerika
    De Wereldgezondheidsorganisatie WHO stelt een noodcomité samen om te onderzoeken of een nieuw ontdekte griepvariant een gevaar vormt voor de internationale volksgezondheid. De variant is ontdekt in Noord-Amerika.

    In Mexico zijn 12 mensen overleden aan de nieuwe griepvariant, zegt de WHO. Van tientallen andere doden wordt dit nog onderzocht. In de VS zijn zeven mensen besmet geraakt, maar al die patiënten overleefden de griep.

    De nieuwe griepvariant is een niet eerder vertoonde combinatie van virussen die onder varkens, vogels en mensen voorkomen.

    Bron: NOS

    Dirk
318 Posts
Pagina: «« 1 ... 11 12 13 14 15 16 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.012
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.528
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.588
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.730
Aedifica 3 903
Aegon 3.258 322.687
AFC Ajax 538 7.087
Affimed NV 2 6.289
ageas 5.844 109.887
Agfa-Gevaert 14 2.049
Ahold 3.538 74.330
Air France - KLM 1.025 35.024
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.692
Allfunds Group 4 1.469
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.819
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 242.925
AMG 971 133.204
AMS 3 73
Amsterdam Commodities 305 6.687
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 490
Antonov 22.632 153.605
Aperam 92 14.975
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.767
Arcelor Mittal 2.033 320.659
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.295
Aroundtown SA 1 219
Arrowhead Research 5 9.730
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.089
ASML 1.766 106.467
ASR Nederland 21 4.452
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.647
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 14 februari

    1. Theon Q4-cijfers
    2. Hermes Q4-cijfers (Fra)
    3. Umicore Q4-cijfers
    4. Consumptie huishoudens december (NL)
    5. Economische groei vierde kwartaal vlpg (NL)
    6. Internationale handel december (NL)
    7. Economische groei vierde kwartaal 2e raming (eur) volitaliteit verwacht
    8. Moderna Q4-cijfers (VS)
    9. Detailhandelsverkopen januari (VS)
    10. Importprijzen januari (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht